Market Overview

India Conjugate Vaccine Market (2018-2023) by Disease Indication and End User - ResearchAndMarkets.com

Share:

The "India
Conjugate Vaccine Market (2018-2023)"
report has been added to ResearchAndMarkets.com's
offering.

India is expected to be the fastest growing market due to the
government's focus on research and development in the life sciences
domain.

By making Pneumococcal Conjugate Vaccine (PCV) available under the
Universal immunization program (UIP), the government of India is
ensuring equitable access to those who need them the most - the
underprivileged and underserved.

HIB is one of the leading causes of bacterial meningitis in India and a
major cause of childhood pneumonia. The introduction of LPV in India is
a significant milestone and a step forward towards accelerating child
survival in India, and progress towards achieving national health goals
and the Millennium Development Goal 4.

Growth Factors

  • India is projected to be the fastest growing market for conjugate
    vaccines during the forecast period. Rapidly increasing population,
    rise in consumer awareness, growing disposable income and healthcare
    expenditure, modernization of healthcare infrastructure, and a growing
    medical tourism industry will drive the growth of the Indian market.

Threats & Key Players

  • The India conjugate vaccine market is expected to have significantly
    high growth. Delayed introduction of conjugate vaccines is likely to
    hold back the conjugate vaccine market. Though the prevalence of
    chronic diseases is high, limited availability and accessibility of
    conjugate vaccines in remote areas can become a cause for concern.
    Complicated manufacturing can also be a major restraint for this
    market.
  • Major conjugate vaccine providers operating in the market are
    GlaxoSmithKline, Pfizer Inc., Merck, Novartis, Sanofi Pasteur, etc.

Key Topics Covered

Chapter 1. Executive Summary

Chapter 2. Market Overview

Chapter 3. India Major Segment Overview - by Disease Indication

Chapter 4. India Major Segment Overview - by End User

Chapter 5. Competitive Landscape

  • GlaxoSmithKline
  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited
  • Bharat Biotech
  • Biological E. Limited
  • Serum Institute of India

For more information about this report visit https://www.researchandmarkets.com/research/s6mg7n/india_conjugate?w=4

View Comments and Join the Discussion!